Age-Specific Stepwise Asthma Management Algorithm
For adults and adolescents ≥12 years with asthma, use ICS-formoterol as both controller and reliever therapy (Track 1/AIR approach) rather than SABA-only or traditional ICS+SABA regimens, as this reduces severe exacerbations by ≥60% compared to SABA alone. 1, 2, 3
ALGORITHM BY AGE GROUP
Ages 0-4 Years
Recurrent Wheezing (Triggered by Respiratory Infections)
- Start: Short course of daily ICS at onset of respiratory tract infection + as-needed SABA
- Do NOT use: FeNO measurement to predict future asthma development (strong recommendation against) 4, 1
Key Point: This applies specifically to children with wheezing only during infections, not those with interval symptoms.
Ages 4-11 Years
Mild to Moderate Persistent Asthma
| Step | Treatment | Notes |
|---|---|---|
| Step 1-2 | As-needed low-dose ICS-formoterol only | Preferred over SABA-only |
| Step 3 | Daily low-dose ICS-formoterol + as-needed ICS-formoterol (MART) | Moderate certainty evidence [4,1] |
| Step 4 | Medium-dose ICS-formoterol MART OR add LAMA | Consider phenotyping |
Critical Caveat: Do NOT increase ICS dose short-term for symptom worsening in adherent patients (conditional recommendation against) 1
Ages 5-11 Years: Additional Considerations
Allergen Immunotherapy
- SCIT: Conditionally recommended as adjunct if asthma is controlled during all phases (initiation, build-up, maintenance) 4, 1
- SLIT: Recommended AGAINST for asthma treatment 1
FeNO Testing (Ages ≥5 years)
- Use: As part of ongoing monitoring strategy when uncertainty exists in choosing/adjusting therapy (conditional recommendation) 4, 1
- Do NOT use: In isolation to assess control or predict exacerbations (strong recommendation against) 4
- Diagnostic adjunct: When diagnosis uncertain and spirometry unavailable/inconclusive 4
Ages 12+ Years (Adolescents and Adults)
TREATMENT TRACK 1 (PREFERRED): Anti-Inflammatory Reliever (AIR) Approach
| Step | Maintenance | Reliever | Evidence Level |
|---|---|---|---|
| 1 | None | As-needed low-dose ICS-formoterol | High (reduces exacerbations 60% vs SABA) [2,3] |
| 2 | None | As-needed low-dose ICS-formoterol | High [2,3] |
| 3 | Low-dose ICS-formoterol daily | As-needed ICS-formoterol (MART) | High [1,3] |
| 4 | Medium-dose ICS-formoterol daily | As-needed ICS-formoterol (MART) | High [1,3] |
| 5 | High-dose ICS-formoterol daily + add-on | As-needed ICS-formoterol (MART) | See below |
Step 5 Add-On Options (in order of consideration):
LAMA (tiotropium): Conditionally recommended to add to ICS-LABA (moderate certainty) 1
- Preferred over adding LAMA to ICS alone when LABA not used 1
Biologic Therapy (severe asthma with Type-2 inflammation):
Azithromycin: For moderate-to-severe asthma (Step 5) 3
Bronchial Thermoplasty: Conditionally recommended AGAINST (low value on harms vs benefits) 1
TREATMENT TRACK 2 (ALTERNATIVE): Traditional SABA-Based Approach
Only if ICS-formoterol unavailable or patient preference after shared decision-making
| Step | Maintenance | Reliever |
|---|---|---|
| 1 | None | As-needed SABA |
| 2 | Daily low-dose ICS | As-needed SABA |
| 3 | Daily low-dose ICS-LABA | As-needed SABA |
| 4 | Daily medium-dose ICS-LABA | As-needed SABA |
| 5 | Daily high-dose ICS-LABA + add-ons | As-needed SABA |
Critical Warning: SABA-only treatment is strongly discouraged across all guidelines due to increased exacerbation risk and mortality 2, 5, 3
MILD PERSISTENT ASTHMA (Ages ≥12): Special Consideration
Two acceptable options (conditional recommendation, moderate certainty):
- Daily low-dose ICS + as-needed SABA
- As-needed ICS-formoterol concomitantly (AIR-only approach)
Preferred: Option 2 (as-needed ICS-formoterol) shows superior exacerbation reduction 1, 3
STEPPING DOWN ALGORITHM
When to Consider (after 3+ months of good control):
- Asthma Control Questionnaire-5 score <0.75
- No exacerbations in past 3-6 months
- Minimal reliever use (<2 times/week)
- Normal lung function for patient
How to Step Down:
- Reduce ICS dose by 25-50%
- If on MART, can transition to as-needed only (Step 3→2→1)
- Review in 1-3 months
- 60% of patients successfully transitioned to lower steps in AIR algorithm trial 6
Common Pitfall: Step-down is recommended but infrequently practiced; actively pursue to minimize adverse effects and costs 7
ALLERGEN MITIGATION STRATEGIES
Conditionally Recommended:
- Integrated pest management (alone or multicomponent) for cockroach allergy 1
- Impermeable pillow/mattress covers ONLY as part of multicomponent intervention for dust mite allergy (NOT as single intervention) 1
Strength: Conditional recommendations, low-to-moderate certainty evidence 1
MONITORING REQUIREMENTS (All Ages)
At Each Visit:
- Asthma control assessment (symptoms, night waking, activity limitation, reliever use)
- Exacerbation history
- Lung function (spirometry when possible)
- Inhaler technique (critical—most common cause of poor control)
- Adherence assessment
- Risk factors (smoking, allergen exposure, comorbidities)
- Type-2 biomarkers (FeNO, blood eosinophils) when adjusting therapy 2
Frequency: Every 1-3 months during adjustment, every 3-12 months when stable 2, 3
ACUTE EXACERBATION MANAGEMENT
Immediate Treatment:
- High-dose SABA via spacer/nebulizer
- Systemic corticosteroids (oral prednisolone 1 mg/kg, max 50 mg, for 5-7 days)
- Oxygen to maintain SpO₂ ≥90% (≥94% in children)
Post-Discharge (Critical):
- Reassess maintenance treatment within 2-7 days
- Provide/review written asthma action plan
- Ensure ICS-containing controller therapy initiated/optimized 2
- Address triggers and modifiable risk factors
SPECIAL POPULATIONS
Severe Asthma (Step 5)
Structured Approach:
- Verify diagnosis (consider alternative diagnoses)
- Optimize modifiable factors (adherence, technique, comorbidities, exposures)
- Inflammatory phenotyping (FeNO, blood eosinophils, IgE)
- Select biologic based on phenotype 2
- Systemic corticosteroid stewardship (minimize/eliminate) 2
Allergic Rhinitis Comorbidity
- INCS + INAH combination preferred over either alone 8
- May benefit from SLIT for rhinitis (though not for asthma) 4
KEY IMPLEMENTATION POINTS
What Changed in Recent Guidelines:
Paradigm Shift: From SABA-based to ICS-formoterol-based reliever therapy across all severity levels 2, 5, 3, 9
Economic Evidence: Strong cost-effectiveness data supports AIR/MART approach 9
Real-World Data: AIR algorithm implementation shows 84.3% patient satisfaction, improved control, and successful step-down in 60% of patients 6
Diagnostic Emphasis: British guidelines emphasize eosinophilic markers; GINA emphasizes reversible airflow limitation; both acknowledge no single gold-standard test 9
Common Pitfalls to Avoid:
- Prescribing SABA-only treatment (increases mortality risk)
- Not checking inhaler technique at every visit
- Failing to step down when appropriate
- Using FeNO in isolation without clinical context
- Short-term ICS dose increases in adherent patients (ineffective)
- Administering SCIT at home (must be in clinical setting with monitoring capacity) 4
PATIENT EDUCATION ESSENTIALS
Must Cover:
- Difference between controller and reliever medications
- Correct inhaler technique (demonstrate and observe)
- Written asthma action plan with specific thresholds
- Trigger identification and avoidance
- When to seek emergency care
- Importance of adherence even when asymptomatic
MEDICATION AVAILABILITY CONSIDERATIONS
If ICS-formoterol unavailable:
- Use Track 2 approach (daily ICS or ICS-LABA + SABA reliever)
- Ensure ICS-containing therapy at minimum
- Never use SABA-only long-term 2, 5, 3
Tiotropium availability:
ONE-PAGE CLINICAL SUMMARY
ASTHMA STEPWISE MANAGEMENT: QUICK REFERENCE
AGES 0-4 YEARS
AGES 4-11 YEARS
- Step 1-2: As-needed ICS-formoterol
- Step 3+: Daily ICS-formoterol + as-needed ICS-formoterol (MART) 4, 1
AGES 12+ YEARS (PREFERRED TRACK 1)
- Step 1-2: As-needed ICS-formoterol only (reduces exacerbations 60%) 2, 3
- Step 3-5: Daily ICS-formoterol + as-needed ICS-formoterol (MART) 1, 3
- Step 5 add-ons: LAMA, biologics, azithromycin 1, 5, 3
NEVER:
- SABA-only treatment long-term 2, 5, 3
- FeNO in isolation 4
- Short-term ICS increases in adherent patients 1
- SCIT at home 4
ALWAYS:
- Check inhaler technique every visit
- Assess adherence
- Provide written action plan
- Consider step-down after 3+ months control 6
- Post-exacerbation review within 2-7 days 2
MONITORING:
- Control assessment, lung function, technique, adherence, risk factors every 1-3 months during adjustment 2, 3
SEVERE ASTHMA:
- Verify diagnosis → Optimize modifiable factors → Phenotype → Biologic selection 2